Literature DB >> 10494835

Role of mitochondria in Parkinson disease.

S Kösel1, G Hofhaus, A Maassen, P Vieregge, M B Graeber.   

Abstract

The cause of the selective degeneration of nigrostriatal neurons in Parkinson disease (PD) has remained largely unknown. Exceptions include rare missense mutations in the alpha-synuclein gene on chromosome 4, a potentially pathogenic mutation affecting the ubiquitin pathway, and mutations in the parkin gene on chromosome 6. However, unlike classical PD, the latter syndrome is not associated with the formation of typical Lewy bodies. In contrast, a biochemical defect of complex I of the mitochondrial respiratory chain has been described in a relatively large group of confirmed PD cases. Recent cybrid studies indicate that the complex I defect in PD has a genetic cause and that it may arise from mutations in the mitochondrial DNA. Sequence analysis of the mitochondrial genome supports the view that mitochondrial point mutations are involved in PD pathogenesis. However, although mitochondria function as regulators in several known forms of cell death, their exact involvement in PD has remained unresolved. This is of relevance because classical apoptosis does not appear to play a major role in the degeneration of the parkinsonian nigra.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10494835     DOI: 10.1515/BC.1999.106

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  14 in total

1.  Proteomic method identifies proteins nitrated in vivo during inflammatory challenge.

Authors:  K S Aulak; M Miyagi; L Yan; K A West; D Massillon; J W Crabb; D J Stuehr
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

Review 2.  The axonal transport of mitochondria.

Authors:  Peter J Hollenbeck; William M Saxton
Journal:  J Cell Sci       Date:  2005-12-01       Impact factor: 5.285

3.  Genetic susceptibility to Parkinson's disease among South and North Indians: I. Role of polymorphisms in dopamine receptor and transporter genes and association of DRD4 120-bp duplication marker.

Authors:  Ramesh C Juyal; Mitashree Das; Sohan Punia; Madhuri Behari; Geetika Nainwal; Sumit Singh; Pazhayannur V Swaminath; Shyla T Govindappa; Sachi Jayaram; Uday B Muthane; B K Thelma
Journal:  Neurogenetics       Date:  2006-07-01       Impact factor: 2.660

4.  Mitochondrial gene therapy augments mitochondrial physiology in a Parkinson's disease cell model.

Authors:  Paula M Keeney; Caitlin K Quigley; Lisa D Dunham; Christina M Papageorge; Shilpa Iyer; Ravindar R Thomas; Kathleen M Schwarz; Patricia A Trimmer; Shaharyar M Khan; Francisco R Portell; Kristen E Bergquist; James P Bennett
Journal:  Hum Gene Ther       Date:  2009-08       Impact factor: 5.695

5.  Cloning of a human cDNA encoding a novel enzyme involved in the elongation of long-chain polyunsaturated fatty acids.

Authors:  A E Leonard; E G Bobik; J Dorado; P E Kroeger; L T Chuang; J M Thurmond; J M Parker-Barnes; T Das; Y S Huang; P Mukerji
Journal:  Biochem J       Date:  2000-09-15       Impact factor: 3.857

6.  Effect of nitric oxide on mitochondrial respiratory activity of human articular chondrocytes.

Authors:  E Maneiro; M J López-Armada; M C de Andres; B Caramés; M A Martín; A Bonilla; P Del Hoyo; F Galdo; J Arenas; F J Blanco
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

7.  Niacin metabolism and Parkinson's disease.

Authors:  Tetsuhito Fukushima
Journal:  Environ Health Prev Med       Date:  2005-01       Impact factor: 3.674

8.  Walking economy in people with Parkinson's disease.

Authors:  Cory L Christiansen; Margaret L Schenkman; Kim McFann; Pamela Wolfe; Wendy M Kohrt
Journal:  Mov Disord       Date:  2009-07-30       Impact factor: 10.338

9.  Hyaluronic acid inhibits nitric oxide-induced apoptosis and dedifferentiation of articular chondrocytes in vitro.

Authors:  Hao Peng; Jian-lin Zhou; Shi-qing Liu; Qiong-jie Hu; Jiang-hua Ming; Bo Qiu
Journal:  Inflamm Res       Date:  2010-01-14       Impact factor: 4.575

10.  Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function.

Authors:  Vanessa A Morais; Patrik Verstreken; Anne Roethig; Joél Smet; An Snellinx; Mieke Vanbrabant; Dominik Haddad; Christian Frezza; Wim Mandemakers; Daniela Vogt-Weisenhorn; Rudy Van Coster; Wolfgang Wurst; Luca Scorrano; Bart De Strooper
Journal:  EMBO Mol Med       Date:  2009-05       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.